Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the RP2D of gedatolisib in combination with talazoparib
and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that
is triple negative or BRCA1/2 positive (deficient).